Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
5 - Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
Published online by Cambridge University Press: 19 October 2021
Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
Summary
Clinicians must be knowledgeable about the mechanisms, metabolic pathways, and kinetics of all prescribed medications, but this is especially true for agents with narrower therapeutic indices such as clozapine. Armed with this information, one can maximize the potential for a successful clozapine trial in a patient who may lack other viable therapeutic options. While the properties underlying clozapine’s unique efficacy profile are not fully elucidated, there are extensive data on peripheral and central nervous system (CNS) kinetics, drug–drug and environmental interactions, and plasma levels to inform routine clinical care. (Throughout this volume clozapine plasma levels will be presented in ng/ml and nmol/l units. Some laboratories may report levels in μg/l, which is exactly equivalent to ng/ml.)
Information
- Type
- Chapter
- Information
- The Clozapine HandbookStahl's Handbooks, pp. 90 - 113Publisher: Cambridge University PressPrint publication year: 2019
References
Golden, G. and Honigfeld, G. (2008). Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia. Clinical Drug Investigation, 28, 231–239.CrossRefGoogle ScholarPubMed
Couchman, L., Morgan, P. E., Spencer, E. P., et al. (2010). Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex). Therapeutic Drug Monitoring, 32, 624–627.Google Scholar
Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., et al. (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. Journal of Clinical Psychopharmacology, 24, 70–78.Google Scholar
Couchman, L., Morgan, P. E., Spencer, E. P., et al. (2010). Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 1993–2007. Therapeutic Drug Monitoring, 32, 438–447.Google Scholar
Meyer, J. M., Proctor, G., Cummings, M., et al. (2016). Ciprofloxacin and clozapine – A potentially fatal but underappreciated interaction. Case Reports in Psychiatry, 2016, 5606098.CrossRefGoogle Scholar
Diaz, F. J., Santoro, V., Spina, E., et al. (2008). Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry, 41, 81–91.Google Scholar
Diaz, F. J., Eap, C. B., Ansermot, N., et al. (2014). Can valproic acid be an inducer of clozapine metabolism? Pharmacopsychiatry, 47, 89–96.Google ScholarPubMed
Zhou, S. F., Wang, B., Yang, L. P., et al. (2010). Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metabolism Reviews, 42, 268–354.Google Scholar
Haslemo, T., Eikeseth, P. H., Tanum, L., et al. (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. European Journal of Clinical Pharmacology, 62, 1049–1053.CrossRefGoogle ScholarPubMed
Faber, M. S. and Fuhr, U. (2004). Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clinical Pharmacology & Therapeutics, 76, 178–184.Google Scholar
Hagg, S., Spigset, O., Mjorndal, T., et al. (2000). Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology, 49, 59–63.Google Scholar
Takeuchi, H., Powell, V., Geisler, S., et al. (2016). Clozapine administration in clinical practice: Once-daily versus divided dosing. Acta Psychiatrica Scandinavica, 134, 234–240.CrossRefGoogle ScholarPubMed
Weiner, D. M., Meltzer, H. Y., Veinbergs, I., et al. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology, 177, 207–216.Google Scholar
Frazier, J. A., Cohen, L. G., Jacobsen, L., et al. (2003). Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. Journal of Clinical Psychopharmacology, 23, 87–91.Google Scholar
Raper, J., Morrison, R. D., Daniels, J. S., et al. (2017). Metabolism and distribution of clozapine-N-oxide: Implications for nonhuman primate chemogenetics. ACS Chemical Neuroscience, 8, 1570–1576.CrossRefGoogle ScholarPubMed
Cummings, J., Isaacson, S., Mills, R., et al. (2014). Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet, 383, 533–540.CrossRefGoogle ScholarPubMed
Meltzer, H. Y., Elkis, H., Vanover, K., et al. (2012). Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. Schizophrenia Research, 141, 144–152.CrossRefGoogle Scholar
Li, C. H., Stratford, R. E. Jr., Velez, de Mendizabal, N., et al. (2014). Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. Journal of Translational Medicine, 12, 203.Google Scholar
Coyle, J. T., Tsai, G. and Goff, D. C. (2002). Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Current Drug Targets – CNS & Neurological Disorders, 1, 183–189.Google Scholar
Lane, H. Y., Huang, C. L., Wu, P. L., et al. (2006). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological Psychiatry, 60, 645–649.Google Scholar
Williams, J. B., Mallorga, P. J., Jeffrey Conn, P., et al. (2004). Effects of typical and atypical antipsychotics on human glycine transporters. Schizophrenia Research, 71, 103–112.Google Scholar
Schwieler, L., Linderholm, K. R., Nilsson-Todd, L. K., et al. (2008). Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sciences, 83, 170–175.Google Scholar
Veerman, S. R., Schulte, P. F., Begemann, M. J., et al. (2014). Clozapine augmented with glutamate modulators in refractory schizophrenia: A review and metaanalysis. Pharmacopsychiatry, 47, 185–194.Google Scholar
Hermida, J., Paz, E. and Tutor, J. C. (2008). Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Therapeutic Drug Monitoring, 30, 41–45.CrossRefGoogle ScholarPubMed
Clark, S. R., Warren, N. S., Kim, G., et al. (2018). Elevated clozapine levels associated with infection: A systematic review. Schizophrenia Research, 192, 50–56.CrossRefGoogle ScholarPubMed
Tio, N., Schulte, P. F. J. and Martens, H. J. M. (2021). Clozapine intoxication in COVID-19. Am J Psychiatry, 178, 123–127.Google Scholar
Meyer, J. M. and Stahl, S. M. (2021). The Clinical Use of Antipsychotic Plasma Levels – Stahl’s Handbooks. New York, NY, Cambridge University Press; 382 pp.Google Scholar
Conley, R. R., Carpenter, W. T. Jr. and Tamminga, C. A. (1997). Time to clozapine response in a standardized trial. American Journal of Psychiatry, 154, 1243–1247.Google Scholar
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C. (Eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition, pp. 279–302. Chicago, IL: McGraw-Hill.Google Scholar
Verbeeck, R. K. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. European Journal of Clinical Pharmacology, 64, 1147–1161.Google Scholar
Doran, A., Obach, R. S., Smith, B. J., et al. (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metabolism and Disposition, 33, 165–174.Google Scholar
Jakobsen, M. I., Larsen, J. R., Svensson, C. K., et al. (2017). The significance of sampling time in therapeutic drug monitoring of clozapine. Acta Psychiatrica Scandinavica, 135, 159–169.CrossRefGoogle ScholarPubMed
Lee, J., Bies, R., Takeuchi, H., et al. (2016). Quantifying intraindividual variations in plasma clozapine levels: A population pharmacokinetic approach. Journal of Clinical Psychiatry, 77, 681–687.Google Scholar
Oo, T. Z., Wilson, J. F., Naidoo, D., et al. (2006). Therapeutic monitoring of clozapine in Australia: The need for consensus. Therapeutic Drug Monitoring, 28, 696–699.Google Scholar
Accessibility standard: Unknown
Why this information is here
This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.Accessibility Information
Accessibility compliance for the HTML of this chapter is currently unknown
and may be updated in the future.